MedPredict Thought Leader Insight & Analysis Reports
One of your key challenges is to stay on top of the latest activities in your target therapeutic categories. What’s happening with competitive compounds in the pipeline? What are their indications and marketing claims likely to be? How are trends in clinical practice evolving, and how will that affect your current and future business?
MedPredict delivers the insights that will drive your strategic decision-making, but without the big price tag and long lead-time required to conduct your own thought leader interviews or market research. We deliver a wide range of syndicated reports, based on in-depth, primary thought leader interviews, that are ready to download today, so you can act on the information right away. And if you don't see what you need in our syndicated reports database, we would be happy to provide you with a customized proposal for proprietary research.
Featured Report: Rheumatoid Arthritis/Gout Q1 2008
Price: USD $6,000
Report Summary: This report was derived from primary interviews with seven North American and European rheumatologists (2 US, 2 UK, 1 Netherlands, 1 Germany, 1 Switzerland). The Panel was asked to opine on the unmet needs in the treatment of gout and the treatment of rheumatoid arthritis. For gout they addressed pipeline drugs that may help them manage their patients who are intolerant to allopurinol. For RA the key issue was switching: How long should anti-TNF therapy be tried? What comes next? And what would challenge anti-TNF therapy for 1st-line usage?
The Panel also talks about a number of developing commercial issues. What will Wyeth do when they return to Amgen the rights to etanercept? How strong is AstraZeneca’s commitment to osteoarthritis?
The Panel discusses the relative merits of, and the most meaningful clinical developments related to:
- BAFF/BLyS and other cell signaling mechanisms vs. B-cell ablation.
- CCR
- p38 MAPK
- Syk
- LTßR-Ig
- Jak
- IL17
- P2X7
- SGRA
- Cathepsin S
- NF-kB
- Fibroblast inhibition
- HDAC
- recombinant human alpha-fetoprotein
- And more.
Drugs mentioned in this report include: allopurinol; febuxostat (Teijin/Ipsen/TAP); Puricase (pegloticase; Savient); Remicade (infliximab; Centocor/Schering-Plough/Essex), Enbrel (etanercept; Wyeth/Amgen); Humira (adalimumab; Abbott), Orencia (abatacept; Bristol-Myers Squibb); MabThera (rituximab; Roche/Biogen/Genentech); methotrexate (generic); denosumab (Amgen); golimumab (Centocor/Schering-Plough/Essex); Actemra (tocilizumab; Roche/Chugai); Cimzia (certolizumab; UCB); GA101 (anti-BR3-Fc / anti-BR3 MAb Biogen / Genentech); LymphoStat-B® (belimumab; Human Genome Sciences / GSK); Atacicept (TACI-Ig; ZymoGenetics / Merck-Serono); BMS-582949 (BMS); 856553 (GSK); CP-690550 (Pfizer); INCB18424 (Incyte); tamatinib (R788; Rigel); baminercept (LTßR-Ig or BG9924; Biogen); MLN-3897 (Millennium / Sanofi-Aventis); AZD5672(AstraZeneca); RWJ-445380 (Alza/J&J); AZD9056 (AstraZeneca); everolimus (RAD-001; Novartis); MM-093 (Merrimack)
Who will benefit from this report: Competitive Intelligence, Marketing, Commercial Analysis, L&A, New Products Planning, R&D, Business Development and Market Research.